# Medical Need of OAC Reversal

> **NCT03254147** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 53969 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** warfarin
- **DRUG:** dabigatran
- **DRUG:** Apixaban
- **DRUG:** Edoxaban
- **DRUG:** Rivaroxaban

## Key facts

- **NCT ID:** NCT03254147
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-15
- **Primary completion:** 2017-10-30
- **Final completion:** 2017-11-10
- **Target enrollment:** 53969 (ACTUAL)
- **Last updated:** 2019-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03254147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03254147, "Medical Need of OAC Reversal". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03254147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*